Genmab — December 2018
-
Vi kan ikke afvise at der er analytikere som har regnet forkert og skal have efterset deres beregninger. Men som jeg har forstaaet er det en fordel at angribe sygdommen MM massivt og i starten af sygdomsforloebet saa derfor tror jeg darzalex bliver 1st valg sammen med andre
-
Netop SB.
-
Novod er til stede på ASH og snakker med folk. Han mener at konsensus-forventning er Maia MRD-neg på mindst 30-40%. Hertil bemærker han, at hvis data ikke lever op til det, så vil det kunne skuffe markedet. Han kommer ikke med noget bud selv. Det er hvad jeg har kunnet læse ud af hans seneste skriv.
-
Man kan da bare kigge på PFS kurven. Så tror jeg patienterne er ligeglade med MRD ? https://ash.confex.com/ash/2018/webprogram/Paper120737.html
-
Torben Plesner på ASH https://twitter.com/michaelodwyermd/status/1069400104296079360?s=21
-
-
-
Bluebird/Celgene bb21217 BCMA CAR-T https://www.marketwatch.com/press-release/bluebird-bio-and-celgene-corporation-present-initial-data-from-ongoing-phase-1-clinical-study-of-next-generation-anti-bcma-car-t-cell-therapy-bb21217-in-patients-with-relapsedrefractory-multiple-myeloma-at-ash-annual-meeting-2018-12-02
-
God morgen.
-
Genopfriskning på R&D Update i dag. https://ir.genmab.com/news-releases/news-release-details/genmab-hold-rd-update-and-2018-ash-data-review-meeting-0
-
https://www.youtube.com/watch?v=iemqPGiyapY Promising Findings for Daratumumab Plus VRd in Multiple Myeloma
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind